» Articles » PMID: 33860184

Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes

Overview
Specialty Biochemistry
Date 2021 Apr 16
PMID 33860184
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Mescaline is a naturally occurring psychoactive alkaloid that has been used as a sacrament by Indigenous populations in spiritual ritual and healing ceremonies for millennia. Despite promising early preliminary research and favorable anecdotal reports, there is limited research investigating mescaline's psychotherapeutic potential. We administered an anonymous online questionnaire to adults ( = 452) reporting use of mescaline in naturalistic settings about mental health benefits attributed to mescaline. We assessed respondents' self-reported improvements in depression, anxiety, post-traumatic stress disorder (PTSD), and alcohol and drug use disorders (AUD and DUD). Of the respondents reporting histories of these clinical conditions, most (68-86%) reported subjective improvement following their most memorable mescaline experience. Respondents who reported an improvement in their psychiatric conditions reported significantly higher ratings of acute psychological factors including mystical-type, psychological insight, and ego dissolution effects compared to those who did not report improvements (Cohen's range 0.7 - 1.5). Many respondents (35-50%) rated the mescaline experience as the single or top five most spiritually significant or meaningful experience(s) of their lives. Acute experiences of psychological insight during their mescaline experience were associated with increased odds of reporting improvement in depression, anxiety, AUD and DUD. Additional research is needed to corroborate these preliminary findings and to rigorously examine the efficacy of mescaline for psychiatric treatment in controlled, longitudinal clinical trials.

Citing Articles

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.

Valdez T, Patel V, Senesombath N, Hatahet-Donovan Z, Hornick M Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598395 PMC: 11597566. DOI: 10.3390/ph17111484.


Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.

Vamvakopoulou I, Nutt D Eur Addict Res. 2024; 30(5):302-320.

PMID: 39321788 PMC: 11527458. DOI: 10.1159/000540062.


A bibliometric analysis of research on psychedelics for depression treatment.

Hua H, Fu X, Wang W, Wang S, Wang D, Wu Z Heliyon. 2024; 10(17):e36886.

PMID: 39281459 PMC: 11401032. DOI: 10.1016/j.heliyon.2024.e36886.


A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder.

Celik M, Gold M, Fuehrlein B Brain Sci. 2024; 14(3).

PMID: 38539681 PMC: 10969323. DOI: 10.3390/brainsci14030294.


Opioid use disorder: current trends and potential treatments.

Lee Y, Gold M, Blum K, Thanos P, Hanna C, Fuehrlein B Front Public Health. 2024; 11:1274719.

PMID: 38332941 PMC: 10850316. DOI: 10.3389/fpubh.2023.1274719.


References
1.
Passie T, Benzenhofer U . MDA, MDMA, and other "mescaline-like" substances in the US military's search for a truth drug (1940s to 1960s). Drug Test Anal. 2017; 10(1):72-80. DOI: 10.1002/dta.2292. View

2.
Roseman L, Nutt D, Carhart-Harris R . Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front Pharmacol. 2018; 8:974. PMC: 5776504. DOI: 10.3389/fphar.2017.00974. View

3.
Rickli A, Moning O, Hoener M, Liechti M . Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016; 26(8):1327-37. DOI: 10.1016/j.euroneuro.2016.05.001. View

4.
Katon W . Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011; 13(1):7-23. PMC: 3181964. View

5.
Palhano-Fontes F, Barreto D, Onias H, Andrade K, Novaes M, Pessoa J . Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2018; 49(4):655-663. PMC: 6378413. DOI: 10.1017/S0033291718001356. View